NO885016L - Fremgangsmaate til fremstilling av antigenspesifikke t-cellelinjer og terapeutisk anvendelse av disse. - Google Patents

Fremgangsmaate til fremstilling av antigenspesifikke t-cellelinjer og terapeutisk anvendelse av disse.

Info

Publication number: NO885016L
Authority: NO; Norway
Prior art keywords: antigen; cells; specific; hcmv; population
Prior art date: 1987-03-11

Application number

NO88885016A

Other languages

English (en)

Norwegian (no)

Other versions

NO885016D0 (no

Inventor

Yung-Nan Liu

Richard C Gehrz

Original Assignee

Childrens Hosp Medical Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-11

Filing date

1988-11-10

Publication date

1989-01-11

1988-02-09 Priority claimed from PCT/US1988/000383 external-priority patent/WO1988007077A1/en

1988-11-10 Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center

1988-11-10 Publication of NO885016D0 publication Critical patent/NO885016D0/no

1989-01-11 Publication of NO885016L publication Critical patent/NO885016L/no

Links

238000000034 method Methods 0.000 title claims description 86
230000001225 therapeutic effect Effects 0.000 title description 16
238000002360 preparation method Methods 0.000 title description 8
239000000427 antigen Substances 0.000 claims description 271
108091007433 antigens Proteins 0.000 claims description 270
102000036639 antigens Human genes 0.000 claims description 270
210000004027 cell Anatomy 0.000 claims description 196
241000701024 Human betaherpesvirus 5 Species 0.000 claims description 176
210000001744 T-lymphocyte Anatomy 0.000 claims description 110
210000005087 mononuclear cell Anatomy 0.000 claims description 97
210000002443 helper t lymphocyte Anatomy 0.000 claims description 63
210000000612 antigen-presenting cell Anatomy 0.000 claims description 62
102000000588 Interleukin-2 Human genes 0.000 claims description 49
108010002350 Interleukin-2 Proteins 0.000 claims description 49
230000003612 virological effect Effects 0.000 claims description 43
230000002062 proliferating effect Effects 0.000 claims description 41
241000700605 Viruses Species 0.000 claims description 39
230000000735 allogeneic effect Effects 0.000 claims description 35
230000035755 proliferation Effects 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 33
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 27
210000002950 fibroblast Anatomy 0.000 claims description 24
241000124008 Mammalia Species 0.000 claims description 23
230000001575 pathological effect Effects 0.000 claims description 20
230000028993 immune response Effects 0.000 claims description 14
239000002552 dosage form Substances 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 13
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 11
102000002068 Glycopeptides Human genes 0.000 claims description 11
108010015899 Glycopeptides Proteins 0.000 claims description 11
230000001965 increasing effect Effects 0.000 claims description 9
101710172711 Structural protein Proteins 0.000 claims description 8
210000004369 blood Anatomy 0.000 claims description 8
239000008280 blood Substances 0.000 claims description 8
230000002163 immunogen Effects 0.000 claims description 8
230000035899 viability Effects 0.000 claims description 6
108060003393 Granulin Proteins 0.000 claims description 5
108010003533 Viral Envelope Proteins Proteins 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
238000007911 parenteral administration Methods 0.000 claims description 5
230000001717 pathogenic effect Effects 0.000 claims description 5
230000001902 propagating effect Effects 0.000 claims description 5
244000052769 pathogen Species 0.000 claims description 4
210000004408 hybridoma Anatomy 0.000 claims description 2
241001465754 Metazoa Species 0.000 claims 1
108010087302 Viral Structural Proteins Proteins 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 description 38
102000004169 proteins and genes Human genes 0.000 description 27
102000003886 Glycoproteins Human genes 0.000 description 25
108090000288 Glycoproteins Proteins 0.000 description 21
230000001472 cytotoxic effect Effects 0.000 description 19
238000011282 treatment Methods 0.000 description 16
208000015181 infectious disease Diseases 0.000 description 15
210000001626 skin fibroblast Anatomy 0.000 description 14
210000000265 leukocyte Anatomy 0.000 description 13
230000004044 response Effects 0.000 description 13
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 12
230000000694 effects Effects 0.000 description 11
239000002609 medium Substances 0.000 description 10
230000009696 proliferative response Effects 0.000 description 10
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
210000003719 b-lymphocyte Anatomy 0.000 description 7
239000003599 detergent Substances 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
239000012894 fetal calf serum Substances 0.000 description 7
230000000670 limiting effect Effects 0.000 description 7
239000000047 product Substances 0.000 description 7
108010092160 Dactinomycin Proteins 0.000 description 6
208000036142 Viral infection Diseases 0.000 description 6
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
229960000640 dactinomycin Drugs 0.000 description 6
239000000284 extract Substances 0.000 description 6
230000007420 reactivation Effects 0.000 description 6
230000009385 viral infection Effects 0.000 description 6
206010011831 Cytomegalovirus infection Diseases 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000012636 effector Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000009169 immunotherapy Methods 0.000 description 5
206010022000 influenza Diseases 0.000 description 5
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
108700016947 Bos taurus structural-GP Proteins 0.000 description 4
102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
241000186362 Mycobacterium leprae Species 0.000 description 4
101710188053 Protein D Proteins 0.000 description 4
101710132893 Resolvase Proteins 0.000 description 4
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
231100000433 cytotoxic Toxicity 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
241000712461 unidentified influenza virus Species 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
208000003322 Coinfection Diseases 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
102100034349 Integrase Human genes 0.000 description 3
102000008072 Lymphokines Human genes 0.000 description 3
108010074338 Lymphokines Proteins 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
230000005714 functional activity Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000004073 interleukin-2 production Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
238000013207 serial dilution Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
241000894007 species Species 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101710121417 Envelope glycoprotein Proteins 0.000 description 2
102000043129 MHC class I family Human genes 0.000 description 2
108091054437 MHC class I family Proteins 0.000 description 2
102000043131 MHC class II family Human genes 0.000 description 2
108091054438 MHC class II family Proteins 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
238000002659 cell therapy Methods 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000013068 control sample Substances 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
230000007402 cytotoxic response Effects 0.000 description 2
230000029142 excretion Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
102000034356 gene-regulatory proteins Human genes 0.000 description 2
108091006104 gene-regulatory proteins Proteins 0.000 description 2
239000003365 glass fiber Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
208000037920 primary disease Diseases 0.000 description 2
210000001978 pro-t lymphocyte Anatomy 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
239000002356 single layer Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
239000003104 tissue culture media Substances 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
230000036642 wellbeing Effects 0.000 description 2
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
241000712891 Arenavirus Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
208000006586 Ectromelia Diseases 0.000 description 1
101710088235 Envelope glycoprotein C homolog Proteins 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
206010024503 Limb reduction defect Diseases 0.000 description 1
241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
101710141347 Major envelope glycoprotein Proteins 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
101710186352 Probable membrane antigen 3 Proteins 0.000 description 1
101710181078 Probable membrane antigen 75 Proteins 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
108010004487 SS-B antigen Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
101710178472 Tegument protein Proteins 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
206010058874 Viraemia Diseases 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000005859 cell recognition Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000005712 elicitor Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003426 epidermal langerhans cell Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
230000012010 growth Effects 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
230000035876 healing Effects 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
238000000703 high-speed centrifugation Methods 0.000 description 1
102000052972 human La Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008073 immune recognition Effects 0.000 description 1
230000037451 immune surveillance Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000002625 monoclonal antibody therapy Methods 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002688 persistence Effects 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000000472 rate-zonal centrifugation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000009121 systemic therapy Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000014723 transformation of host cell by virus Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000002476 tumorcidal effect Effects 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Landscapes

Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO88885016A 1987-03-11 1988-11-10 Fremgangsmaate til fremstilling av antigenspesifikke t-cellelinjer og terapeutisk anvendelse av disse. NO885016L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2457187A	1987-03-11	1987-03-11
PCT/US1988/000383 WO1988007077A1 (en)	1987-03-11	1988-02-09	Method for the generation of antigen-specific t cell lines and therapeutic use thereof

Publications (2)

Publication Number	Publication Date
NO885016D0 NO885016D0 (no)	1988-11-10
NO885016L true NO885016L (no)	1989-01-11

Family

ID=26698602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO88885016A NO885016L (no)	1987-03-11	1988-11-10	Fremgangsmaate til fremstilling av antigenspesifikke t-cellelinjer og terapeutisk anvendelse av disse.

Country Status (2)

Country	Link
DK (1)	DK628088A (da)
NO (1)	NO885016L (da)

1988
- 1988-11-10 DK DK628088A patent/DK628088A/da not_active Application Discontinuation
- 1988-11-10 NO NO88885016A patent/NO885016L/no unknown

Also Published As

Publication number	Publication date
DK628088D0 (da)	1988-11-10
NO885016D0 (no)	1988-11-10
DK628088A (da)	1989-01-11

Publication	Publication Date	Title
US20220251509A1 (en)	2022-08-11	Platform for activation and expansion of virus-specific t-cells
US12533407B2 (en)	2026-01-27	Methods of selecting T cell line and donor thereof for adoptive cellular therapy
JP7364237B2 (ja)	2023-10-18	癌治療のためのｔ細胞の活性化方法
Engers et al.	1981	Inhibition of T cell-mediated functions by MVM (i), a parvovirus closely related to minute virus of mice.
Riddell et al.	1991	Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients
Zhao et al.	2002	Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8+ and CD4+ T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells
WO1988007077A1 (en)	1988-09-22	Method for the generation of antigen-specific t cell lines and therapeutic use thereof
JP2025106402A (ja)	2025-07-15	がん治療のためのｔ細胞の活性化方法
JP2004512039A (ja)	2004-04-22	ヒトサイトメガロウィルスｐｐ１５０の免疫反応性ペプチドｃｔｌエピトープ
Jalili et al.	2022	Virus-specific T cells: Promising adoptive T cell therapy against infectious diseases following hematopoietic stem cell transplantation
Kurane et al.	1986	Characterization with monoclonal antibodies of human lymphocytes active in natural killing and antibody-dependent cell-mediated cytotoxicity of dengue virus-infected cells
CN107904259A (zh)	2018-04-13	一种治疗艾滋病合并淋巴瘤的car‑t细胞及其制备方法和应用
Yasukawa et al.	1990	Rotavirus induces proliferative response and augments non‐specific cytotoxic activity of lymphocytes in humans
Nowakowska et al.	2015	T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus–transformed B cells
Kishimoto et al.	2000	Protection against murine coxsackievirus B3 myocarditis by T cell vaccination
Foster et al.	2003	Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy
NO885016L (no)	1989-01-11	Fremgangsmaate til fremstilling av antigenspesifikke t-cellelinjer og terapeutisk anvendelse av disse.
Yasukawa et al.	1983	HLA-restricted T lymphocyte-mediated cytotoxicity against herpes simplex virus-infected cells in humans
Vaz-Santiago et al.	2002	IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy
CA2562892A1 (en)	2005-10-27	Bob-1 specific t cells and methods to use
Rutella et al.	2011	Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation
Heslop	2006	Commentary on Journal of Immunotherapy Paper by Melenhorst et al
Jalili et al.	0	Sayahinouri M, Dehghani Ghorbi M, Roshandel E, Aghdami N. Virus-Specific T cells: Promising Adoptive T Cell Therapy against Infectious Diseases following Hematopoietic
Uhlin et al.	2012	Salvage T Cell Therapy for Therapy Resistant Viral Diseases After Stem Cell Transplantation
Meij et al.	2011	Treatment of refractory cytomegalovirus reactivation after allogeneic stem cell transplantation with in vitro generated cytomegalovirus pp65-specific CD8+ T cell lines